NCT06790095Enrolling By Invitation2 期
Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Precision Medicine Part 3 - Option II
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- Enrolling By Invitation
- 入组人数
- 26
- 试验地点
- 3
- 主要终点
- Change in Disability Rating Score (DRS)
研究概览
简要总结
The purpose of this study is to determine if experimental drug treatment improves recovery after TBI as compared to a control (placebo) group. Changes in recovery will be measured throughout the study. The study drug listed below is approved by the U.S. Food and Drug Administration (FDA) but is being used "off-label" in this study. This means that the drug is not currently approved to treat TBI.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults (18-65 years of age, inclusive)
- •Head injury warranting clinical evaluation with a non-contrast cranial CT based on American College of Emergency Physicians (ACEP) Centers for Disease Control and Prevention (CDC) clinical policy for TBI imaging.
- •Able to receive investigational product within 24 hours of head injury.
- •Closest, prior to randomization GCS score of 3 to 12 (motor score < 6)
- •Evidence of TBI on imaging, confirmed by:
- •Evidence of contusion and/or
- •Evidence of traumatic axonal microvascular injury (TAMVI)
- •Initial Glial Fibrillary Acidic Protein (GFAP) blood level ≥ 1000 pg/mL ≤ 15000 pg/mL determined using a for Research Use Only (RUO) assay(s) or an Investigation Use Only (IUO) assay(s)
- •Participants able to undergo Magnetic Resonance Imaging (MRI) scans, no contraindications
- •Legally Authorized Representative (LAR) willing and able to provide informed consent
- •Participant/LAR able to read, speak, and understand English
排除标准
- •Isolated epidural hematoma
- •Bilaterally fixed dilated pupils in the absence of paralytic medications, or evidence of herniation on cranial CT
- •Pre-existing conditions including disabling developmental, neurologic, psychiatric, medical disorder that continues to produce functional disability up to the time of injury; or imminent death based on clinical judgement
- •Order for comfort care placed prior to enrollment
- •Current enrollment in another interventional study
- •Currently pregnant or currently breastfeeding or planning on becoming pregnant in the next 6M
- •Current incarceration or in custody
- •On psychiatric hold (e.g. codes 5150, 5250)
- •Ongoing pre-injury therapy with the Investigational Product (IP), currently receiving immunosuppressive therapy, chemotherapy, or any contraindicated medications (see CsA Drug contraindications/caution table in the Pharmacy Manual)
- •Current or medical history of any allergic reactions and/or anaphylactic reactions towards cyclosporine (CsA) and cremophor (also known as kolliphor®)
- •Severe polytrauma or previous conditions that would preclude conducting any study activities
- •Any spinal cord injury of grade A to D on the American Spinal Injury Association (ASIA) Impairment Scale
- •Primary diagnosis at the enrolling facility of ischemic or hemorrhagic stroke
- •Body Mass Index (BMI) >35
- •Hemodynamic instability, per participating site physician investigator clinical judgement
- •Current or medical history of nephrectomy, renal dysfunction, significant renal failure, or high-risk for renal failure, defined as:
- •Creatinine Clearance (CrCl) or estimated Glomerular Filtration Rate (eGFR) (<60 mL/minute/1.73 m2)
- •Major rhabdomyolysis with creatine kinase > 5,000 IU/L
- •Current or medical history of hepatic disease (e.g., liver laceration at time of injury with Abbreviated Injury Scale for Liver Lacerations > 1); cirrhosis), or serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >3 times the upper limit of normal lab value at the screening/baseline visit.
- •Current or medical history of serious chronic viral or fungal infection.
- •Current or medical history of active mycobacterial infection or anti-tuberculous treatment.
- •Medical history of human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus antibody.
- •Any significant disease or disorder (including abnormal laboratory tests) which, in the opinion of the participating site investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study.
- •Low likelihood of follow up or study compliance, or any other reason, in the opinion of the participating site investigator, the participants should not participate in the study.
研究组 & 干预措施
Cyclosporine (CsA)
Active Comparator
Intravenous (IV) injection, 2.5 mg/kg loading dose given over 2 hours, followed by a 3-day (72-hour) constant IV infusion of 5 mg/kg/day.
干预措施: Cyclosporine (CsA) (Drug)
Matching Placebo
Placebo Comparator
Intravenous (IV) injection of 0.9% NaCl over 74 hours.
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Disability Rating Score (DRS)
时间窗: Baseline to Week 4 post-injury
The primary outcome measure is to determine whether the intervention safely improves functional outcome in participants with TBI as compared to placebo, as measured by the change in the Disability Rating Score (DRS) score from Baseline to Week 4 post-injury.
次要结局
- Change in Blood-based biomarker (Neurofilament light chain)(Baseline to Week 2 post-injury)
- Change in Blood-based biomarker (GFAP)(Baseline to Week 2 post-injury)
- Change in Blood-based biomarker (UCH-L1)(Baseline to Week 2 post-injury)
- Post-TBI symptom outcome (CRSR-FAST)(Baseline to Week 4 post-injury)
- Imaging biomarkers(Week 2 to Month 6)
- Post-TBI functional outcomes (DRS)(Baseline to Month 3 and Baseline to Month 6)
- Post-TBI functional outcomes (FSE)(Week 2, Week 4, Month 3 and Month 6)
- Post-TBI functional outcomes (GOSE-TBI)(Week 2, Week 4, Month 3 and Month 6)
- Post-TBI cognitive outcome (BTACT)(Week 4, Month 3, and Month 6)
- Post-TBI quality of life and patient-reported outcomes (QOLIBRI)(Month 3 and Month 6)
- Post-TBI quality of life and patient-reported outcomes (RPQ)(Month 3 and Month 6)
- Post-TBI quality of life and patient-reported outcomes (Caregiver Burden)(Month 3 and Month 6)
- Post-TBI quality of life and patient-reported outcomes (Caregiver Burden)(Week 2, Month 3, and Month 6)
研究者
研究点 (3)
Loading locations...
相似试验
Unknown
2 期
Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain InjuryTraumatic Brain InjuryNCT05826912University of California, San Francisco672
招募中
早期 1 期
Stimulating After Recovery From Traumatic Brain InjuryTBI (Traumatic Brain Injury)NCT05327829University of Minnesota30
已完成
不适用
"Interactive Metronome Technology for Blast-Related Traumatic Brain Injury"Traumatic Brain InjuryPost-Concussion SyndromeNCT01248390The Defense and Veterans Brain Injury Center48
招募中
不适用
Noninvasive Vagal Nerve Stimulation and Cognitive RehabilitationTraumatic Brain InjuryNCT06589362Shirley Ryan AbilityLab60
已完成
不适用
Improving Health Outcomes With Resource FacilitationTraumatic Brain InjuryRehabilitationInterventionNCT04462549Rehabilitation Hospital of Indiana90